By otakuyassine3@gmail.com 
Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,530,000 shares, an increase of 25.9% from the November 30th total of 2,010,000 shares. Approximately 8.2% of the company’s shares are sold short. Based on an average daily volume of 328,900 shares, the days-to-cover ratio is presently 7.7 days.
Insider Buying and Selling at Tyra Biosciences
In other Tyra Biosciences news, CEO Todd Harris sold 10,035 shares of Tyra Biosciences stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $24.31, for a total value of $243,950.85. Following the completion of the transaction, the chief executive officer now directly owns 1,467,338 shares of the company’s stock, valued at $35,670,986.78. The trade was a 0.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Nina S. Kjellson sold 27,493 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.56, for a total transaction of $455,284.08. Following the sale, the director now directly owns 458,506 shares in the company, valued at $7,592,859.36. This represents a 5.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,660 shares of company stock valued at $1,839,047 over the last quarter. 15.40% of the stock is owned by company insiders.
Institutional Trading of Tyra Biosciences
Several institutional investors have recently modified their holdings of TYRA. HighVista Strategies LLC acquired a new stake in Tyra Biosciences during the 2nd quarter worth $257,000. Franklin Resources Inc. purchased a new position in shares of Tyra Biosciences during the third quarter worth about $278,000. Valence8 US LP acquired a new stake in shares of Tyra Biosciences during the third quarter worth about $310,000. SG Americas Securities LLC purchased a new stake in shares of Tyra Biosciences in the 3rd quarter valued at about $311,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Tyra Biosciences in the 3rd quarter valued at about $333,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
Tyra Biosciences Stock Down 4.3 %
Tyra Biosciences stock traded down $0.63 during midday trading on Friday, reaching $14.07. The company’s stock had a trading volume of 112,645 shares, compared to its average volume of 196,195. The company has a market cap of $711.98 million, a P/E ratio of -8.74 and a beta of 1.01. The business has a 50-day simple moving average of $16.85 and a 200-day simple moving average of $19.39. Tyra Biosciences has a fifty-two week low of $11.24 and a fifty-two week high of $29.60.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, equities analysts forecast that Tyra Biosciences will post -1.57 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have recently weighed in on TYRA. Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. HC Wainwright cut their price target on Tyra Biosciences from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Finally, Oppenheimer boosted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 19th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $31.00.
Read Our Latest Research Report on Tyra Biosciences
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
Receive News & Ratings for Tyra Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Tyra Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.